Gliosarcoma

Gliosarcoma is a rare and aggressive primary malignant brain tumor classified as a variant of glioblastoma (WHO grade IV). It is characterized by a biphasic tissue pattern containing both glial (gliomatous) and mesenchymal (sarcomatous) components, which distinguishes it from conventional glioblastoma. Gliosarcoma accounts for approximately 2-8% of all glioblastoma cases and predominantly affects the central nervous system, most commonly arising in the cerebral hemispheres, particularly the temporal lobe. Symptoms of gliosarcoma depend on the tumor's location and size and may include headaches, seizures, progressive neurological deficits such as weakness or speech difficulties, cognitive changes, personality alterations, and signs of increased intracranial pressure including nausea and vomiting. The tumor tends to grow rapidly and may occasionally metastasize outside the central nervous system, which is uncommon for most primary brain tumors. The current treatment approach for gliosarcoma mirrors that of glioblastoma and typically involves maximal safe surgical resection followed by concurrent radiation therapy and temozolomide chemotherapy (the Stupp protocol). Despite aggressive multimodal treatment, the prognosis remains poor, with a median overall survival generally reported between 6 and 16 months. Recurrence is common, and treatment options at recurrence are limited, including repeat surgery, re-irradiation, bevacizumab, and clinical trials investigating novel therapeutic approaches. Research into the molecular characteristics of gliosarcoma is ongoing to identify potential targeted therapies.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Gliosarcoma